Pharmacoepidemiologic usage analysis of neuroleptics for treating paranoid schizophrenia in psychiatry hospital

2003 ◽  
Vol XXXV (1-2) ◽  
pp. 39-43
Author(s):  
A. V. Kuchaeva ◽  
L. E. Ziganshina ◽  
K. K. Yakhin ◽  
L. M. Minnetdinova ◽  
F. F. Gatin ◽  
...  
Keyword(s):  
Side Effects ◽  
Paranoid Schizophrenia ◽  
Psychotropic Medications ◽  
Motor Reaction ◽  
Neuroleptic Therapy ◽  
Usage Analysis

During pharmacotherapy with neuroleptics of paranoid schizophrenia patients there had been studied retrospectively and perspectively frequency and expressiveness of side effects. There was determined a correlation between neuro-motor reaction expressiveness of neuroleptics and sex, age and time of intake. The obtained results can be very useful to a practioner for his/ her rational usage of psychotropic medications, removal of neuro- motor reaction and making decision in continuation of neuroleptic therapy.

Tardive Dyskinesia: A Concern for the Pediatrician

PEDIATRICS ◽  
1986 ◽  
Vol 77 (4) ◽  
pp. 553-556
Author(s):  
HARVEY S. SINGER
Keyword(s):  
Side Effects ◽  
Tardive Dyskinesia ◽  
Children And Adolescents ◽  
Behavior Disorders ◽  
Antipsychotic Drugs ◽  
Extrapyramidal Side Effects ◽  
Body Movements ◽  
Neuroleptic Therapy

Antipsychotic drugs, such as the phenothiazines (chlorpromazine, fluphenazine, thioridazine), butyrophenones (haloperiodol), and diphenylbutylpiperidines (pimozide) are used in children and adolescents to treat a variety of clinical entities including psychoses, tics, behavior disorders, and movement problems. Because virtually all of these drugs have a potential to affect body movements and posture, they have also been termed neuroleptics.1 Most physicians are aware of the more common acute extrapyramidal side effects of these drugs, such as oculogyria, pseudoparkinsonism, dystonia, and restlessness (akathisia). Despite the widespread use of neuroleptics, however, little is known about the long-term neurologic consequences of such treatment. Of particular concern, based originally on data in adults, is the risk of severe and persistent tardive dyskinesia developing in persons receiving neuroleptic therapy.

scholarly journals Psychotropic Drugs: Implications For Dental Practice

2008 ◽  
Vol 55 (3) ◽  
pp. 89-99 ◽  
Author(s):  
Daniel E. Becker
Keyword(s):  
Anxiety Disorder ◽  
Side Effects ◽  
Drug Interactions ◽  
Dental Care ◽  
Psychotropic Drugs ◽  
Preoperative Assessment ◽  
Psychotropic Medications ◽  
Dental Practice ◽  
Dental Patients ◽  
Psychiatric Illnesses

Abstract Appropriate preoperative assessment of dental patients should always include analysis of their medications. Psychiatric illnesses including panic/anxiety disorder, depression, psychoses, and manic disorders are prevalent within our society. An impressive number of drug formulations are prescribed for these disorders, and they introduce concern regarding side effects and possible drug interactions with medications the dentist may deem necessary for dental care. This article will address essential pharmacology of these psychotropic medications.

Unanticipated Psychotropic Medication Reactions

2006 ◽  
Vol 28 (3) ◽  
pp. 218-240 ◽  
Author(s):  
H. Gray Otis ◽  
Jason H. King
Keyword(s):  
Side Effects ◽  
Psychotropic Medications ◽  
Ethical Question ◽  
Mental Health Counselors ◽  
Drug Trials ◽  
Client Outcomes ◽  
Medication Regimen ◽  
Clinical Drug Trials ◽  
As Effects ◽  
Clinical Drug

Research from a variety of sources demonstrates that psychotropic medications have induced a number of unanticipated physiological and psychological client reactions. Although a great deal of literature is published concerning potential expected side effects from psychotropic medications, little is understood regarding other unexpected reactions that may cause significant client discomfort. These unanticipated psychotropic reactions may be considered as effects that may be rare and therefore not accounted for in randomized clinical drug trials. Like any medication, psychotropic medications do not produce the same effect in everyone. Some people may respond better to one medication than another. Mental health counselors are advised to be aware that some unexpected reactions can be important in determining client outcomes. In this article, we discuss the client's right to be informed about unanticipated side-effects of their medication regimen and the ethical question as to how much information to give clients.

Antipsychotic Effects of Cannabidiol

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1 ◽  
Author(s):  
F.M. Leweke ◽  
D. Koethe ◽  
F. Pahlisch ◽  
D. Schreiber ◽  
C.W. Gerth ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Paranoid Schizophrenia ◽  
Treatment Strategies ◽  
Endocannabinoid System ◽  
Psychotic Symptoms ◽  
Controlled Clinical Trial ◽  
Antipsychotic Treatment ◽  
Double Blind ◽  
Acute Schizophrenia

Background:In contrast to delta-9-tetrahydrocannabinol, the phytocannabinoid cannabidiol does not exert psychotomimetic effects. Cannabidiol was suggested a re-uptake inhibitor of anandamide and potential antipsychotic properties have been hypothesized for it. We therefore performed a clinical trial to investigate thesis hypothesis and to clarify the underlying link to the neurobiology of schizophrenia.Methods:We performed an explorative, 4-week, double-blind, controlled clinical trial on the effects of purified cannabidiol in acute schizophrenia compared to the antipsychotic amisulpride. The antipsychotic properties of both drugs were the primary target of the study. Furthermore, side-effects and anxiolytic capabilities of both treatments were investigated.Results:42 patients fulfilling DSM-IV criteria of acute paranoid schizophrenia participated in the study. Both treatments were associated with a significant decrease of psychotic symptoms after 2 and 4 weeks as assessed by BPRS and PANSS. However, there was no statistical difference between both treatment groups. In contrast, cannabidiol induced significantly less side effects (EPS, increase in prolactin, weight gain) when compared to amisulpride.Conclusions:Cannabidiol revealed substantial antipsychotic properties in acute schizophrenia. This is in line with our suggestion of an adaptive role of the endocannabinoid system in paranoid schizophrenia, and raises further evidence that this adaptive mechanism may represent a valuable target for antipsychotic treatment strategies.The Stanley Medical Research Institute (00-093 to FML) and the Koeln Fortune Program (107/2000 + 101/2001 to FML) funded this study.

Placebos in Clinical Trials of Psychotropic Medication

1997 ◽  
Vol 42 (3) ◽  
pp. 1-6 ◽  
Author(s):  
Donald Addington ◽  
Richard Williams ◽  
Yvon Lapierre ◽  
Nady El-Guebaly
Keyword(s):  
Clinical Trials ◽  
Side Effects ◽  
High Risk ◽  
Psychotropic Medication ◽  
Psychotropic Drugs ◽  
Placebo Response ◽  
Response Rates ◽  
Psychotropic Medications ◽  
Placebo Controls

This paper represents the position of the Canadian Psychiatric Association on the ethical and scientific issues related to the use of placebos in the evaluation of new psychotropic drugs. The position taken by the Association is that new psychotropic medications must be shown to be effective and must be weighed against the best current interventions. Placebo controls may be appropriate under certain circumstances, even when an established intervention is effective. These include situations in which placebo response rates are high, variable, or close to response rates for effective therapies. Placebo controls arc also appropriate when established interventions cany a high risk of side effects or are effective against only certain symptoms of the disorder.

scholarly journals Dynamics of Quality of Life Indices in Case of Metabolic Syndrome in Patients with Paranoid Schizophrenia on the Background of Atypical Neuroleptic Agents Application and Improvement of Comorbidity

2019 ◽  
Author(s):  
Ivan Romash ◽  
Mykhailo Vynnyk
Keyword(s):  
Quality Of Life ◽  
Metabolic Syndrome ◽  
Short Form ◽  
Paranoid Schizophrenia ◽  
Atypical Neuroleptic ◽  
Group Iii ◽  
Neuroleptic Therapy ◽  
Group I ◽  
The Impact

The objective of the research was to study the features of quality of life dynamics depending on clinical and psychopathological symptoms in patients with paranoid schizophrenia asso ciated with metabolic syndrome on the background of long-term neuroleptic therapy and to study the eff ectiveness of concomitant corrective therapy. 140 patients with paranoid schizophrenia (F20.0) were examined and divided into three groups. Group I included 40 patients who received haloperidol at an ave rage daily dose of 4.6 ± 1.3 mg/day, Group II consisted of 40 patients who received risperidone (3.7 ± 1.8 mg/day), Group III included 40 patients who received quetiapine (413 ± 116 mg/day). Half of the patients in each of the presented groups continued to receive neuroleptic therapy according to the above mentioned regimen, and the other half of the patients received metformin hydro chloride at a dose of 500 mg/day in addition to the standard therapy. The cont rol group consisted of 20 patients diag nosed with "paranoid schizophrenia, remission", without metabolic syndrome signs, who had not received neuroleptics for the past six months. The Positive and Negative Syndrome Scale (PANSS) and the Medical Outcomes Study 36-Item Short-Form Health Status Questionnaire (SF-36) were used to study the patients’ mental health in detail. In this research, we monitored the impact of comorbidity on quality of life indices in the patients with long-lasting treatment of schizophrenia by neuroleptic agents, and noted that concomitant corrective therapy was appropriate in terms of compliance increase and quality of life indices improvement in the studied category of patients. Keywords: paranoid schizophrenia, metabolic syndrome, atypical neuroleptic agents, quality of life

The Other Side of Psychopharmacology: A Review of the Literature

2006 ◽  
Vol 28 (4) ◽  
pp. 309-337 ◽  
Author(s):  
Thomas L. Murray, Jr.
Keyword(s):  
Side Effects ◽  
Medical Model ◽  
Psychotropic Medications ◽  
The Other ◽  
Review Of The Literature ◽  
Counselor Identity ◽  
Literature Reviews ◽  
Theoretical Assumptions ◽  
Recent Developments ◽  
And Training

A number of literature reviews exist that support the use of psychotropic medications. This article provides a review of the disconfirming literature regarding psychopharmacology use. Comparing the first review of psychopharmacology published in the counseling field two decades earlier to what is known currently, I examine recent developments in psychopharmacology research focusing on the safety, efficacy, side-effects, and theoretical assumptions of various classes of psychotropic medications. This article concludes by addressing counselor identity, practice and training concerns vis-à-vis psychiatric medications and the medical model.

Dermatologic Side Effects of Psychotropic Medications

2014 ◽  
Vol 55 (1) ◽  
pp. 1-20 ◽  
Author(s):  
Mario V. Mitkov ◽  
Ryan M. Trowbridge ◽  
Benjamin N. Lockshin ◽  
Jason P. Caplan
Keyword(s):  
Side Effects ◽  
Psychotropic Medications
Sign in / Sign up

Export Citation Format

Share Document